Dr Reddy's eyes Plan B for Nexium generic amid Q3 slip
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories reported a 7% decline in net profit at INR5.7bn ($91m) for the third quarter ended December 2014, dented by impairment charges even as firm's top brass indicated that they were keeping a close eye on currency headwinds in emerging markets like Russia.